Abstract
Rebecca E. Graff, Henrik L. Bengtsson, Jung H. Suh, Adam B. Olshen, Elizabeth Y. Wang, Ryan M. Allen, Stacey A. Kenfield, Janet E. Cowan, Peter R. Carroll, Jeff Simko, June M. Chan
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The diagnosis and treatment of prostate cancer: a review
10.1001/jama.2017.7248 · 2017
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3
10.1200/jco.2008.20.4669 · 2009
Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy Gleason score and PSA: a population-based study of modern patients
10.1016/j.ijrobp.2015.01.051 · 2015
Low-risk prostate cancer and tumor upgrading in the surgical specimen: analysis of clinical factors predicting tumor upgrading in a contemporary series of patients who were evaluated according to the modified Gleason score grading system
10.1159/000447164 · 2017
Heterogeneity in D'Amico classification-based low-risk prostate cancer: differences in upgrading and upstaging according to active surveillance eligibility
10.1016/j.urolonc.2015.04.004 · 2015
The metabolic landscape of prostate cancer
10.1016/j.euo.2018.06.010 · 2019
Metabolomics biomarkers of prostate cancer: a systematic review
10.3390/diagnostics9010021 · 2019
Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence
10.1158/1055-9965.epi-15-1223 · 2016
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics
10.3390/metabo11030181 · 2021
Metabolic profiling in formalin-fixed and paraffin-embedded prostate cancer tissues
10.1158/1541-7786.mcr-16-0262 · 2017
Metabolomics of prostate cancer Gleason score in tumor tissue and serum
10.1158/1541-7786.mcr-20-0548 · 2021
The potential role of fatty acids in prostate cancer determined by GC-MS analysis of formalin-fixed paraffin-embedded tissue samples
10.1016/j.jpba.2021.113907 · 2021
Unresolved referenced work
Kept as external metadata until matched
Assessment of small metabolites in plasma, formalin-fixed paraffin-embedded tumor and normal tissue in men with prostate cancer
2018
Metabolomic signatures of aggressive prostate cancer
10.1002/pros.22704 · 2013
A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry
10.1093/bioinformatics/btn506 · 2008
Preoperative metabolic signatures of prostate cancer recurrence following radical prostatectomy
10.1021/acs.jproteome.8b00926 · 2019
Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition
10.1186/s12916-017-0885-6 · 2017
Plasma free amino acid profiling of five types of cancer patients and its application for early detection
10.1371/journal.pone.0024143 · 2011
Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition
10.1074/jbc.m116.771931 · 2017
Prostate cancer cells in different androgen receptor status employ different leucine transporters
10.1002/pros.23263 · 2017
EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer
10.1186/s12964-019-0400-0 · 2019
Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor
10.18632/oncotarget.16775 · 2017
Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study
10.1002/ijc.29576 · 2015
Plasma metabolomic profiles and risk of advanced and fatal prostate cancer
10.1016/j.euo.2019.07.005 · 2021
limma powers differential expression analyses for RNA-sequencing and microarray studies
10.1093/nar/gkv007 · 2015
Serine and glycine metabolism in cancer
10.1016/j.tibs.2014.02.004 · 2014
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
10.1038/nature11743 · 2013
The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer
10.1007/s11255-019-02261-8 · 2019
Cellular metabolism and disease: what do metabolic outliers teach us
10.1016/j.cell.2012.02.032 · 2012
Human prostate cancer is characterized by an increase in urea cycle metabolites
10.3390/cancers12071814 · 2020
The context-specific roles of urea cycle enzymes in tumorigenesis
10.1016/j.molcel.2021.08.005 · 2021
Reprogramming of serine, glycine and one-carbon metabolism in cancer
10.1016/j.bbadis.2020.165841 · 2020
Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection
10.1016/j.mehy.2013.02.008 · 2013
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation
10.1126/science.1218595 · 2012
Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells
10.1038/cddis.2013.393 · 2013
Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status
10.1186/s12885-020-06908-z · 2020
Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7
10.1002/pros.24145 · 2021
Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer
10.1002/cam4.1767 · 2018
Prospective serum metabolomic profiling of lethal prostate cancer
10.1002/ijc.32218 · 2019
Detection of metabolites discriminating subtypes of thyroid cancer: molecular profiling of FFPE samples using the GC/MS approach
10.1016/j.mce.2015.09.021 · doi-reference
A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer
10.1038/s41374-021-00612-7 · doi-reference
Lipidomic analysis of archival pathology specimens identifies altered lipid signatures in ovarian clear cell carcinoma
10.3390/metabo11090597 · doi-reference
High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue
10.1038/nprot.2016.081 · doi-reference
High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples
10.1002/path.4560 · doi-reference
Metabolic profiling of formalin-fixed paraffin-embedded tissues discriminates normal colon from colorectal cancer
10.1158/1541-7786.mcr-19-1091 · doi-reference
UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed, paraffin‑embedded and optimal cutting temperature6‑embedded materials
10.3892/ijo.2019.4898 · doi-reference
The effect of sample age on the metabolic information extracted from formalin-fixed and paraffin embedded tissue samples using desorption electrospray ionization mass spectrometry imaging
10.1016/j.jmsacl.2021.10.004 · doi-reference
A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue
10.1038/nprot.2012.024 · doi-reference
Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma
10.1371/journal.pone.0025357 · doi-reference
Distinct metabolic signatures of hormone-sensitive and castration-resistant prostate cancer revealed by a (1)H NMR-based metabolomics of biopsy tissue
10.1021/acs.jproteome.0c00282 · doi-reference
NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer
10.1016/j.cca.2019.10.046 · doi-reference
The urinary sarcosine/creatinine ratio is a potential diagnostic and prognostic marker in prostate cancer
10.12659/msm.909949 · doi-reference
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol
10.1371/journal.pone.0014175 · doi-reference
Serum methionine metabolites are risk factors for metastatic prostate cancer progression
10.1371/journal.pone.0022486 · doi-reference
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
10.1038/nature07762 · doi-reference
Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer
10.1002/ijc.31313 · doi-reference
Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: a preliminary investigation
10.1016/j.prnil.2017.03.005 · doi-reference
A landscape of metabolic variation across tumor types
10.1016/j.cels.2017.12.014 · doi-reference
Rapid prostate cancer noninvasive biomarker screening using segmented flow mass spectrometry-based untargeted metabolomics
10.1021/acs.jproteome.0c00006 · doi-reference
Preclinical evaluation of (11)C-sarcosine as a substrate of proton-coupled amino acid transporters and first human application in prostate cancer
10.2967/jnumed.116.173179 · doi-reference
1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling
10.1158/1538-7445.am2014-5068 · doi-reference
Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer
10.18632/oncotarget.6370 · doi-reference
Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score
10.1007/s11306-020-01694-y · doi-reference
Rapid diagnosis of prostate cancer disease progression using paper spray ionization mass spectrometry
10.1021/acs.analchem.1c00943 · doi-reference
Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways
10.1093/nar/gkt161 · doi-reference
Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery
10.1038/s41598-020-60616-z · doi-reference
Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
10.1093/carcin/bgt176 · doi-reference
The role of sarcosine metabolism in prostate cancer progression
10.1593/neo.13314 · doi-reference
Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
10.1038/bjc.2016.305 · doi-reference